Abstract 258P
Background
Ovarian cancer leaves a detrimental effect on sexual health due to treatment modalities, hormonal imbalance, inability to accept body image after treatment related deformity and other psychological reasons. As the proportion of ovarian cancer survivors is increasing, it is very important to address the issue of sexual health in these patients, an issue which is generally unaddressed. The aim of our study was to asses sexual health in patients treated for ovarian cancer who were disease free at the time of analysis.
Methods
This single institute prospective study was conducted from April 2017 to November 2017. During the routine follow up visit to the hospital, patients who were disease free were recruited in the study. European Organisation of Research and Treatment for Cancer (EORTC) QLQ-OV 28 questionnaire was used to assess the sexual health. The impact of various factors on quality of life (QOL) scores was analysed using one-way analysis of variance (Univariate ANOVA). A p value of < 0.05 was considered as statistically significant.
Results
A total of 84 ovarian cancer patients were recruited. Median age at presentation was 45 years. All patients were clinically and biochemically disease free at the time of analysis. Seventy-two patients were married whereas 12 women were either unmarried or divorced or widows. Out of these 72 women, only 34 (47%) women were found to have had sex in last 3 months. A median score of 33.3 (22.2-66.6) was recorded for sexual function in QLQ-OV 28 questionnaire which was lesser than other domains of functional scale. The sexual score was significantly affected by presence of co-morbidities (p < 0.007), higher number of chemotherapy cycles (p < 0.001), fear of recurrence (p < 0.02), vaginal dryness and pain (p < 0.04).
Conclusions
Sexual health is a fundamental quality of life domain which is often compromised and underestimated in ovarian cancer patients. The present study showed that diagnosis and treatment of ovarian cancer has a negative impact on sexual health. As the proportion of ovarian cancer survivors continuously rising, there is a need to acknowledge and address the impact of treatment on sexual health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract